Danette Daniels is a Vice President of the Protein Degrader Platform at Foghorn Therapeutics developing therapeutic degraders in the areas of chromatin regulation and oncology. She was an early leader in the field of targeted protein degradation, pioneering approaches to monitor cellular kinetics of degradation, understanding mechanism of action, and co-developing a new PROTAC modality. She is a member of numerous committees including the AACR Chemistry in Cancer Research Steering Committee and the HESI TPD Safety Initiative. She will be a co-chair for the 2025 AACR New Drugs on the Horizon sessions as well as leading a new Gordon Research Conference series, Induced Proximity Modalities and Therapeutics, that is set to begin in June 2026. In February of 2023 she co-founded the Women in TPD and Induced Proximity Initiative which is nearing 1000 members and offers a mentorship program in addition to conference travel scholarships to early career scientists. Prior to Foghorn Therapeutics, she received her PhD in Biophysics at Yale University, was a postdoctoral fellow at Stanford School of Medicine studying the Wnt signaling pathway, and a Group Leader at Promega Corporation involved in the development of HaloTag, NanoLuc, HiBiT, and NanoBRET technology applications.